Pseudohypericin

ID: ALA1614664

Chembl Id: CHEMBL1614664

Max Phase: Preclinical

Molecular Formula: C30H16O9

Molecular Weight: 520.45

Molecule Type: Small molecule

Associated Items:

Names and Identifiers

Synonyms: Pseudohypericin

Canonical SMILES:  Cc1cc(O)c2c(=O)c3c(O)cc(O)c4c5c(O)cc(O)c6c(=O)c7c(O)cc(CO)c8c1c2c(c34)c(c65)c78

Standard InChI:  InChI=1S/C30H16O9/c1-7-2-9(32)19-23-15(7)16-8(6-31)3-10(33)20-24(16)28-26-18(12(35)5-14(37)22(26)30(20)39)17-11(34)4-13(36)21(29(19)38)25(17)27(23)28/h2-5,31-37H,6H2,1H3

Standard InChI Key:  YXBUQQDFTYOHQI-UHFFFAOYSA-N

Alternative Forms

  1. Parent:

    ALA1614664

    PSEUDOHYPERICIN

Associated Targets(non-human)

Txnrd1 Thioredoxin reductase 1, cytoplasmic (45279 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Txnrd2 Thioredoxin reductase 2, mitochondrial (18 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
GLR1 Glutathione reductase (23 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: YesOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 520.45Molecular Weight (Monoisotopic): 520.0794AlogP: 4.26#Rotatable Bonds: 1
Polar Surface Area: 175.75Molecular Species: ACIDHBA: 9HBD: 7
#RO5 Violations: 2HBA (Lipinski): 9HBD (Lipinski): 7#RO5 Violations (Lipinski): 2
CX Acidic pKa: 6.04CX Basic pKa: 3.36CX LogP: 6.42CX LogD: 4.40
Aromatic Rings: 8Heavy Atoms: 39QED Weighted: 0.12Np Likeness Score: 0.86

References

1. Obach RS, Lombardo F, Waters NJ..  (2008)  Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.,  36  (7): [PMID:18426954] [10.1124/dmd.108.020479]
2. Sorrentino F, Karioti A, Gratteri P, Rigobello MP, Scutari G, Messori L, Bindoli A, Chioccioli M, Gabbiani C, Bergonzi MC, Bilia AR..  (2011)  Hypericins and thioredoxin reductase: Biochemical and docking studies disclose the molecular basis for effective inhibition by naphthodianthrones.,  19  (1): [PMID:21106380] [10.1016/j.bmc.2010.10.045]

Source